Francis Cuss is a physician-scientist, with a background in general and academic medicine, who has developed a broad experience in pharmaceutical research, in clinical development and in executive management within globally-operating biopharma companies during a career of more than 30 years in the pharmaceutical industry; specifically with Bristol-Myers Squibb, Schering-Plough and Glaxo.

Francis retired from Bristol-Myers Squibb in July 2017 having served as Executive Vice President, Chief Scientific Officer and head of R&D since July 2013 and as a member of BMS’s Senior Management Team since 2010. He joined Bristol-Myers Squibb in 2003, and as head of Research for nearly a decade Francis led a very productive discovery organization which produced a pipeline of innovative medicines from both in-house and external programs; helping numerous patients prevail against serious disease and laying the foundation for significant company growth.

He is a member of the board of directors of Novo Holdings A/S, Denmark and Rubius Therapeutics, and Vice Chair of the Board of Trustees of Montclair State University, NJ.

Prior to joining the pharmaceutical industry, Francis was a practicing physician with a specialization in pulmonary medicine in the UK. He received his education and medical training in the United Kingdom. He holds medical degrees from Cambridge University, U.K. and is a fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He has published numerous articles and book chapters on topics of medical interest and organizational effectiveness.

View Francis’s LinkedIn profile here